Wednesday, July 07, 2010 5:04:28 PM
The newest and ever more prevalent religion of the US is technology. Everyone, no matter their station or credentials, slips into a reverie of ideas. What then distinguishes the likes of NNVC? Nothing special about their genius, but rather their drive and will to champion what was an idea. Such entities are walking along, whistling a song, and bam comes an idea! What then? Ahh,now begins the grind... buffeted as they are by motives both contributory, and negative... based on every imaginable human nature frailty. Always there is an ox gored, which disposes same to undermine, and preserve threatened turf.
Yes "the best and brightest.." more often as science becomes increasingly specialize, such persons are like Einstein was, meeting dozens of, and being assailed by dozens more, of the three or four who marginally understand new ideas.
NNVC is truly off on a sensible tangent... new conceptions, newly enabled by instruments and methods which are new, and enabling the pathway not previously traveled.
Me? Dazzeled but feet on the ground... Am I in? IN SPADES!
Yes "the best and brightest.." more often as science becomes increasingly specialize, such persons are like Einstein was, meeting dozens of, and being assailed by dozens more, of the three or four who marginally understand new ideas.
NNVC is truly off on a sensible tangent... new conceptions, newly enabled by instruments and methods which are new, and enabling the pathway not previously traveled.
Me? Dazzeled but feet on the ground... Am I in? IN SPADES!
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
